Sanofi - Aventis Groupe: Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic

Related Keywords

Japan ,Paris ,France General ,France ,United States ,American ,Eva Schaefer Jansen ,Sandrine Guendoul ,Surya Bhatt ,Gewinn Nur ,Tarik Elgoutni ,Sally Bain ,Vesna Tosic ,Felix Lauscher ,Sharon Chen ,Nathalie Pham ,American Thoracic Society ,Regeneron Pharmaceuticals Inc ,Twitter ,Trial Program ,International Conference ,Nasdaq ,Clinical Research Program ,Euronext ,Exchange Commission ,Regeneron Genetics Center ,Pulmonary Research ,Dupilumab Development Program ,New England Journal ,Thoracic Society ,England Journal ,Recently Published Pulmonary ,Clinical Trial Results ,Birmingham Division ,Critical Care Medicine ,Respiratory Questionnaire ,Evaluating Respiratory Symptoms ,Forward Looking Statements ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Digital Media ,Regeneron Pharmaceuticals ,Product Candidates ,Sanofi ,Eventis ,Roupe ,Dress ,Release ,Dupixent ,Dupilumab ,Gate ,Breaking ,Hase ,Copd ,Results ,Resented ,Psimultaneously ,Published ,England ,Journal ,Medicine ,